Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy announces a collaboration with a research consortium backed by a DoD grant to study Traumakine, their intravenous interferon beta treatment, for preventing injuries in battlefield casualties. The study, named RESTOR, seeks to improve survival and limb salvage by using Traumakine as a preemptive treatment before the application of a tourniquet, a strategy that could lead to market approval based on pre-clinical results. Positive outcomes from the RESTOR study could pave the way for Traumakine’s accelerated path to market without the need for extensive human clinical trials.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
